• My Image

    RaiseFor Founders

    We help talented founders raise capital fast at higher valuations

  • My Image

    ScaleFor Companies

    We help commercial health companies scale through supply chains

  • My Image

    InnovateFor Partners

    We solve corporate innovation problems and increase ROI

THE HS. INNOVATION ECOSYSTEMWhat HS. Does

HS. is an innovation ecosystem that builds and scales health startups to tackle global health issues. We work with founders, startup teams, health providers and corporates to improve health and patient care through innovation.

My Image

ENTREPRENEURS, STARTUPS, SCALEUPS AND LISTED COMPANIESFor Founders And Companies


Our HS. programme helps your company to raise capital and close sales at lightning speed.

Join HS.

Our flagship programme is designed to help the best companies and talented founders. We have thrown the rule book away and redesigned the traditional accelerator model with a specific focus on health and healthcare. Our objective is to help you raise investment and close sales as quickly as possible.

SOLVE INNOVATION CHALLENGES, CONNECT WITH STARTUPSFor Partners

HS. partners with key multi-national companies with active sales channels in health, healthcare and health insurance and enables them to connect with commercially-viable innovative health tech companies and integrate them into their supply chains.

We understand that for large corporations it can be almost impossible to find the best companies and products to help them solve key problems. We do the hard work for you, ensuring product-market fit, that the company can scale and that there is a health economics case behind any procurement decision.

AS SEEN IN

THE LATEST FROM HS. AND THE HS.COMMUNITYHS.NEWS

Could The NHS Really Sell Its Data For $12 Billion?

110 min read

HS. cofounder Dr. James Somauroo's latest for Forbes: A new report by consulting firm EY suggests that if the U.K. National Health Service (NHS) datasets were put to use, their value could be up to £9.6 billion ($12 billion) per year.

HS.Podcast - Episode 35: The Story of Flagship Pioneering and The Future of Medicines 🧪

296 min read

James is joined by Dr. Paul-Peter Tak, Venture Partner at Flagship Pioneering and CEO of Kintai Therapeutics. Over a more than 25-year career in the life sciences, Paul-Peter has created and led multiple companies. From 2011 until 2017, Paul-Peter founded and served as senior vice president and head of the immuno-inflammation therapy area unit at GSK.

Feebris Raise £1.1M

61 min read

HS. portfolio company Feebris has announced a successful seed investment raise of £1.1 million. The funding enables the company to continue its innovation in AI for precision diagnosis of respiratory conditions in elderly patients in the UK and young children in India.


Stay updated with our latest info. Join the HS. Community

Thanks for subscribing